1. The Digitization of Your Genetic Information
Genetic Information Privacy
“The federal laws that deal with genetic information are GINA (the Genetic Information Nondiscrimination Act of 2008) and, more recently, HIPAA.”
“Title II of GINA prohibits the use of genetic information to discriminate in employment decisions, such as hiring, firing, and promoting. It also restricts employers from asking for or buying genetic information.”
“The federal Equal Employment Opportunity Commission (EEOC) investigates and enforces GINA claims.”
“Life insurance: The federal GINA does not protect against discrimination in life insurance underwriting based on genetic information. (See the National Human Genome Research Institute’s GINA Fact Sheet, especially the section “What’s not included?”) Life insurers require you to release your medical records when you apply.”
“overly broad compelled authorizations…in states where individuals must sign a release for substantially all of their health records as a condition of employment…or goverment benefits…”
“Genetic information is different: analysis of an individual’s DNA is highly informative about his or her offspring, siblings, and parents.”
By consenting to the current weak laws governing privacy of genetic information, I could be surrenduring any aspects of my future offspring’s natural immunity to COVID/SARS to for-profit organizations.
HHS’ Office for Civil Rights is responsible for enforcing the Privacy and Security Rules. Enforcement of the Privacy Rule began April 14, 2003 for most HIPAA covered entities.
Executive Order 13145 to Prohibit Discrimination in Federal Employment Based on Genetic Information
February 8, 2000
By the authority vested in me as President of the United States by the Constitution and the laws of the United States of America, it is ordered as follows:
Section 1. Nondiscrimination in Federal Employment on the Basis of Protected Genetic Information.
1-101. It is the policy of the Government of the United States to provide equal employment opportunity in Federal employment for all qualified persons and to prohibit discrimination against employees based on protected genetic information, or information about a request for or the receipt of genetic services. This policy of equal opportunity applies to every aspect of Federal employment.
“vaccines are aiming at merely attenuating the milder symptoms and the ‘life-saving’ justification is largely inappropriate”
Moderna’s Patent Estate: Messenger RNA Technologies (mRNA) & Delivery Technologies
Along the way, we have amassed a broad and deep patent estate. This includes foundational patents in modified mRNA technologies and delivery technologies that are essential for mRNA…
To date, Moderna has been granted more than 240 patents in the United States, Europe, Japan and other jurisdictions, protecting fundamental inventions in the mRNA therapeutics space…
I took a look at the PDF files of Moderna’s patents. Learned even more new things…
New words: -BLAST (basic local alignment search tool) algorithm -Codon Optimization Tool -proprietary methods -ENST transcripts (functional gene annotation)
From what I see, companies can use my genetic material from COVID test kits and have a field day with:
GeneArt Gene Synthesis | Thermo Fisher Scientific – US
“…algorithm utilizes a multifactorial approach” – tweaking their algorithms
“…customized DNA constructs” – creating custom DNA/RNA fragments off my genetic material
“significantly improve protein expression” – optimize their algoritim codes that govern building complex protein sequences
“optimal expression of your target genes in the species of your choice” – improve their algorithms to “better deal” with the rare codon in a target gene. in other words to closely resemble the entire, original DNA structure they want to edit and copy
* So what if the BLAST algorithms fail to efficiently perform according to the sequence databases in its software program? Overall program failure on the first attempt to replicate an mRNA sequence? Or fails after multiple replication sequences?
Center for Drug Evaluation and Research | CDER | FDA
“CDER ensures truth in advertising for prescription drugs and monitors the use of marketed drugs for unexpected health risks. If unexpected risks are detected after approval, CDER takes action to inform the public, change a drug’s label, or–if necessary–remove a product from the market.”
FDA has failed to update advertising of COVID innoculation with updated possibilities of adverse reaction. Has failed to suspend and/or terminate the vaccination campaign.
* Questioning how rigorious is the quality and integrity of test data related to non-clinical safety studies of COVID-19 vaccines/ mRNA vaccines.
* This subject also includes the history of the computer software used in mRNA vaccine research and development. What if there was software patches made that the company’s executive board deemed critical? Constantly changing the gene-editing software.
What is GLP (Good Laboratory Practice)?
“First, GLP is a quality management system, not a scientific management system. Or, in other words, GLP defines a set of quality standards for study conduct, data collection, and results reporting. GLP does not define scientific standards. If a study follows GLP, then you can be reasonably sure that the reported results were collected as outlined in the study protocol; however, you cannot be sure that the study actually addresses the scientific hypothesis. In the world of cooking, GLP would ensure that someone follows the recipe exactly as written; however, it does not assure you that the recipe was good or that the resulting item will be tasty!”
Search for FDA Guidance Documents
The Emergency Use Authorization (EUA) authority allows FDA to help strengthen the nation’s public health protections against CBRN threats by facilitating the availability and use of MCMs needed during public health emergencies.
Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN [ Chemical, Biological, Radiological and Nuclear (CBRN) Threats ] threat agents when there are *** no adequate, approved, and available alternatives. ***
“AlgorithmHub – Platform to develop and deploy algorithms”
“…allowing rapid deployment of cloud products using high-level numerical computing languages.”
“The platform also provides solutions to publish algorithms to a repository where it can be monetized.”
Has a CRADA with NSA Hawaii.
Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2
Published: Oct 29, 2020
Cooperative Research and Development Agreement (CRADA)
“Under the CRADA, the FDA will use a range of Organ-Chips from Emulate to study the safety, efficacy, and mechanisms of drugs regulated by the FDA….
This new CRADA agreement follows the successful completion of the first Emulate CRADA with the FDA initiated in 2017 that focused on toxicity studies using the Liver-Chip.”
Financials: Example of Enterprise Value
Emulate Stock – ForgeGlobal.com
About Emulate, Inc.
Emulate Inc. is a privately held company that creates living products for understanding how diseases, medicines, chemicals, and foods affect human health. Our lab-ready Human Emulation System® includes three components: Zoë® Culture Module, Organ-Chips, and analytical software applications. The platform provides a window into the inner workings of human biology and disease
Emulate holds the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for the Organs-on-Chips technology and related systems.
Congressional Research Development: Legal Issues in COVID-19 Vaccine Development and Deployment
Updated November 25, 2020
Congress’s authority to mandate vaccination, on the other hand, must emanate from its enumerated powers in the Constitution. Two potential sources of such power, the Spending Clause and the Commerce Clause, are subject to certain constraints that can limit the scope of a federal vaccination mandate.
Legal liability for injuries caused by a COVID-19 vaccine is likely to be subject to specialized rules under the Public Readiness and Emergency Preparedness (PREP) Act. To encourage the expeditious development and deployment of medical countermeasures, the Secretary of HHS declared COVID-19 a public health emergency and invoked the PREP Act for COVID-19 countermeasures. Under HHS’s declaration, covered persons—including COVID-19 vaccine developers, manufacturers, distributors, and health care professionals who administer a vaccine—are generally immune from legal liability for losses relating to administration or use of an FDA-approved COVID-19 vaccine, except for willful misconduct resulting in death or serious physical injury. However, individuals who are harmed by a COVID-19 vaccine may seek compensation through the Countermeasures Injury Compensation Program, a regulatory process administered by HHS
Key Research Words:
*Quantum Circuit Layouts * trapped ion quantum computer * Circuit optimization, gate alignment, and spin echoes
*various circuit optimizers to attempt to reduce the number of gates * Fundamentals of Layout Design for Electronic Circuits
* Lattice graph / grid lattice
* kinematics, the space of different states. The dynamics describes how these numbers change with time
* Quantum superposition * Quantum-inspired genetic algorithms
“Although AI has made rapid progress over the past decade, it has not yet overcome technological limitations.”
Quantum Artificial Intelligence in 2021: in-Depth Guide